Description

Strain Information

Former Names B6N.129P2-Il27ratm1Mak v/J    (Changed: 20-JUL-12 ) Type Congenic; Mutant Strain; Targeted Mutation; Additional information on Genetically Engineered and Mutant Mice. Visit our online Nomenclature tutorial. Additional information on Congenic nomenclature. Mating System Heterozygote x Heterozygote         (Female x Male)   10-JUL-12 Species laboratory mouse Generation N10pN1+ (10-JUL-12) Generation Definitions   Donating Investigator Dr. Tak Mak,   University Health Network/Un of Toronto

Description
In this knockout strain, a neo cassette replaces part of the extracellular fibronectin type III domain of the interleukin 27 receptor, alpha (Il27ra or WSX-1) gene, abolishing gene function. WSX-1 a class I cytokine receptor expressed mainly in T cells and myeloid cells of the spleen, thymus, and lymph nodes. WSX-1 is an early inducer of T helper 1 (Th1) cell differentiation and helps regulate cell-mediated immunity. Homozygotes are viable and fertile. These WSX-1 KO mice exhibit impaired interferon-γ (IFN-γ) production during early stages of Leishmania major infection. In contrast, Mycobacterium tuberculosis infection results in enhanced CD4⁺ T cell activation and IFN-γ production. Natural killer T (NKT) cells from WSX-1 KO mice with Con A-induced hepatitis produced more IFN-γ and interleukin (IL)-4, with hyperproduction of proinflammatory cytokines IL-1, IL-6, and tumor necrosis factor (TNF)-α. These mice are useful for studying the regulation of Th1/Th2-induced cytokine production during infection and inflammation.

Development
A targeting vector was designed to replace the exon encoding part of the extracellular fibronectin type III domain of the interleukin 27 receptor, alpha (Il27ra) gene with a neomycin resistance (neo) cassette. The construct was electroporated into 129P2/OlaHsd-derived E14K embryonic stem (ES) cells. Correctly targeted ES cells were injected into C57BL/6NTac blastocysts and the resulting chimeric males were bred to C57BL/6NTac females. These mice were backcrossed to C57BL/6NTac mice for at least 10 generations. Upon arrival at The Jackson Laboratory Repository, mice were bred to C57BL/6NJ (Stock No. 005304) for at least one generation to establish the colony.

Control Information

	Control
	Wild-type from the colony
	005304 C57BL/6NJ	(approximate)
Considerations for Choosing Controls

Phenotype

Phenotype Information

View Mammalian Phenotype Terms

Mammalian Phenotype Terms provided by MGI

      assigned by genotype

Il27ra^tm1Mak/Il27ra^tm1Mak

        B6.129P2-Il27ra^tm1Mak

• mortality/aging
• increased sensitivity to xenobiotic induced morbidity/mortality
  • in Con A-treated mice   (MGI Ref ID J:88618)
• immune system phenotype
• *normal* immune system phenotype   (MGI Ref ID J:88618)
• • abnormal T-helper 1 physiology
    • homozygotes display only an initial impairment of IFN-gamma production and induction of Th1 responses during the early stages of infection with an intracellular pathogen   (MGI Ref ID J:89509)
    • in a model of experimental autoimmune uveoretinitis, mice exhibit lower Th1 response compared with wild-type mice   (MGI Ref ID J:116610)
  • decreased circulating interferon-gamma level
    • in the early phase of experimental autoimmune uveoretinitis   (MGI Ref ID J:116610)
  • decreased interferon-gamma secretion
    • in vitro, isolated mutant T cells produce decreased IFN-gamma levels upon primary stimulation with IL-12 plus ConA or anti-CD3   (MGI Ref ID J:89509)
    • however, surprisingly, fully differentiated mutant Th1 cells subjected to a secondary stimulation with ConA produce wild-type levels of IFN-gamma   (MGI Ref ID J:89509)
    • in stimulated CD4+ T cells   (MGI Ref ID J:116610)
  • decreased susceptibility to experimental autoimmune uveoretinitis
    • in the early phase, with lower Th1 response   (MGI Ref ID J:116610)
    • sub-retinal transplants fail to transfer experimental autoimmune uveoretinitis   (MGI Ref ID J:116610)
  • increased T cell proliferation
    • in vitro, mutant splenocytes show a slight increase in proliferation in response to stimulation with increasing concentrations of anti-CD3 or ConA   (MGI Ref ID J:89509)
    • purified mutant splenocytes show a relative increase in the number of cells in the S and G2+M phases of the cell cycle upon stimulation with anti-CD3 plus anti-CD28   (MGI Ref ID J:89509)
    • mutant splenocytes show normal dose-response kinetics in response to stimulation with anti-CD3 plus IL-12, but exhibit a higher proliferation rate than wild-type splenocytes at all but the highest dose of IL-12 upon co-stimulation with anti-CD28   (MGI Ref ID J:89509)
  • increased circulating interferon-gamma level
    • in Con A-treated mice   (MGI Ref ID J:88618)
  • increased circulating interleukin-1 beta level
    • in Con A-treated mice   (MGI Ref ID J:88618)
  • increased circulating interleukin-12 level
    • in Con A-treated mice   (MGI Ref ID J:88618)
  • increased circulating interleukin-4 level
    • in Con A-treated mice   (MGI Ref ID J:88618)
  • increased circulating interleukin-6 level
    • in Con A-treated mice   (MGI Ref ID J:88618)
  • increased circulating tumor necrosis factor level
    • in Con A-treated mice   (MGI Ref ID J:88618)
  • increased interferon-gamma secretion
    • in Con A-stimulated liver mononuclear cells   (MGI Ref ID J:88618)
  • increased interleukin-4 secretion
    • in Con A-stimulated liver mononuclear cells   (MGI Ref ID J:88618)
  • increased susceptibility to bacterial infection
    • following infection with Myobacterium bovis bacillus Calmette-Guerin (BCG), homozygotes exhibit 8 times more liver granulomas than control littermates at 2 weeks post-infection   (MGI Ref ID J:89509)
    • although mutant granulomas are abnormally large and poorly differentiated, no differences in liver CFU number or liver damage are observed relative to similarly-infected wild-type mice   (MGI Ref ID J:89509)
    • although mutant splenocytes produce less IFN-gamma in response to anti-CD3 plus IL-12 than wild-type cells at day 2 post-infection, IFN-gamma production is restored to normal levels at at day 7, and serum IFN-gamma levels are comparable to wild-type levels at 2 weeks post-infection   (MGI Ref ID J:89509)
  • increased susceptibility to parasitic infection
    • homozygotes exhibit increased susceptibility to Leishmania major infection, showing increased footpad swelling, more severe footpad ulcerations, and increased parasite burdern relative to control littermates   (MGI Ref ID J:89509)
    • infected homozygotes exhibit an abnormal initial Th1 response, as shown by impaired IFN-gamma production by popliteal lymph node CD4⁺ lymphocytes during the early phases of Leishmania major infection (at day 5 and 2 weeks post-infection), but not during the later phases (at 4 and 6 weeks post-infection) when both IFN-gamma expression and production levels are restored to wild-type levels   (MGI Ref ID J:89509)
    • in contrast, IL-4 expression is normal at day 5 but elevated at 2 weeks post-infection or later, concomittant with higher serum levels of IgG1 and IgE at 9 weeks post-infection, indicating a deviation toward a Th2 cytokine profile   (MGI Ref ID J:89509)
• liver/biliary system phenotype
• hepatic necrosis
  • in Con A-treated mice   (MGI Ref ID J:88618)
• homeostasis/metabolism phenotype
• decreased circulating interferon-gamma level
  • in the early phase of experimental autoimmune uveoretinitis   (MGI Ref ID J:116610)
• increased circulating alanine transaminase level
  • at a low dose of Con A   (MGI Ref ID J:88618)
  • however, treatment with anti-IFN-gamma or anti-IL4 antibodies or depletion of NK cells lowers ALT levels   (MGI Ref ID J:88618)
• increased circulating interferon-gamma level
  • in Con A-treated mice   (MGI Ref ID J:88618)
• increased circulating interleukin-1 beta level
  • in Con A-treated mice   (MGI Ref ID J:88618)
• increased circulating interleukin-12 level
  • in Con A-treated mice   (MGI Ref ID J:88618)
• increased circulating interleukin-4 level
  • in Con A-treated mice   (MGI Ref ID J:88618)
• increased circulating interleukin-6 level
  • in Con A-treated mice   (MGI Ref ID J:88618)
• increased circulating tumor necrosis factor level
  • in Con A-treated mice   (MGI Ref ID J:88618)
• increased sensitivity to xenobiotic induced morbidity/mortality
  • in Con A-treated mice   (MGI Ref ID J:88618)
• increased susceptibility to injury
  • mice exhibit increased sensitivity to Con A-induced liver injury with increased mortality and increased cytokine serum levels compared with wild-type mice   (MGI Ref ID J:88618)
  • mice treated with a low dose of Con A exhibit increased alanine transaminase serum levels and massive liver necrosis compared with similarly treated wild-type mice   (MGI Ref ID J:88618)
• hematopoietic system phenotype
• *normal* hematopoietic system phenotype
  • homozygotes display normal hematopoietic and lymphoid development relative to wild-type and heterozygous control mice   (MGI Ref ID J:89509)
• • increased T cell proliferation
    • in vitro, mutant splenocytes show a slight increase in proliferation in response to stimulation with increasing concentrations of anti-CD3 or ConA   (MGI Ref ID J:89509)
    • purified mutant splenocytes show a relative increase in the number of cells in the S and G2+M phases of the cell cycle upon stimulation with anti-CD3 plus anti-CD28   (MGI Ref ID J:89509)
    • mutant splenocytes show normal dose-response kinetics in response to stimulation with anti-CD3 plus IL-12, but exhibit a higher proliferation rate than wild-type splenocytes at all but the highest dose of IL-12 upon co-stimulation with anti-CD28   (MGI Ref ID J:89509)
• cellular phenotype
• increased T cell proliferation
  • in vitro, mutant splenocytes show a slight increase in proliferation in response to stimulation with increasing concentrations of anti-CD3 or ConA   (MGI Ref ID J:89509)
  • purified mutant splenocytes show a relative increase in the number of cells in the S and G2+M phases of the cell cycle upon stimulation with anti-CD3 plus anti-CD28   (MGI Ref ID J:89509)
  • mutant splenocytes show normal dose-response kinetics in response to stimulation with anti-CD3 plus IL-12, but exhibit a higher proliferation rate than wild-type splenocytes at all but the highest dose of IL-12 upon co-stimulation with anti-CD28   (MGI Ref ID J:89509)

The following phenotype information may relate to a genetic background differing from this JAX^® Mice strain.

Il27ra^tm1Mak/Il27ra^tm1Mak

        involves: 129P2/OlaHsd * C57BL/6

• immune system phenotype
• increased susceptibility to induced arthritis
  • in an E. coli-induced arthritis model, mice exhibit longer sustained inflammation and greater bone erosion compared with wild-type mice   (MGI Ref ID J:151552)
• skeleton phenotype
• increased susceptibility to induced arthritis
  • in an E. coli-induced arthritis model, mice exhibit longer sustained inflammation and greater bone erosion compared with wild-type mice   (MGI Ref ID J:151552)

View Research Applications

Research Applications

This mouse can be used to support research in many areas including:

Immunology, Inflammation and Autoimmunity Research
Growth Factors/Receptors/Cytokines

Research Tools
Immunology and Inflammation Research
      genes regulating susceptibility to infectious disease and endotoxin

Genes & Alleles

Gene & Allele Information provided by MGI

Allele Symbol		Il27ratm1Mak
Allele Name		targeted mutation 1, Tak Mak
Allele Type		Targeted (knock-out)
Common Name(s)		IL-27R-; Il27ra-; WSX-1-;
Mutation Made By		Dr. Tak Mak,   University Health Network/Un of Toronto
Strain of Origin		129P2/OlaHsd
Gene Symbol and Name		Il27ra, interleukin 27 receptor, alpha
Chromosome		8
Gene Common Name(s)		CRL1; IL-27R; IL-27RA; IL27R; T cell cytokine receptor; TCCR; Tccr; WSX-1; WSX1; zcytor1;
General Note		Phenotypic Similarity to Human Syndrome: Membranous glomerulonephritis (MGN; WHO class V)
Molecular Note		An exon encoding a portion of the extracellular fibronectin type III domain was replaced with a neo cassette. Western blot demonstrated lack of protein in mutant spleen cells. [MGI Ref ID J:89509]

Genotyping

Genotyping Information

Genotyping Protocols

Il27ra^tm1Makalternate2,

SEPARATED MELT

Il27ra^tm1Makalternate2, Separated PCR

Helpful Links

Genotyping resources and troubleshooting

References

References provided by MGI

Selected Reference(s)

Yoshida H; Hamano S; Senaldi G; Covey T; Faggioni R; Mu S; Xia M; Wakeham AC; Nishina H; Potter J; Saris CJ; Mak TW. 2001. WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection. Immunity 15(4):569-78. [PubMed: 11672539]  [MGI Ref ID J:89509]

Additional References

Il27ra^tm1Mak related

Anderson CF; Stumhofer JS; Hunter CA; Sacks D. 2009. IL-27 regulates IL-10 and IL-17 from CD4+ cells in nonhealing Leishmania major infection. J Immunol 183(7):4619-27. [PubMed: 19748991]  [MGI Ref ID J:152775]

Artis D; Johnson LM; Joyce K; Saris C; Villarino A; Hunter CA; Scott P. 2004. Cutting edge: early IL-4 production governs the requirement for IL-27-WSX-1 signaling in the development of protective Th1 cytokine responses following Leishmania major infection. J Immunol 172(8):4672-5. [PubMed: 15067040]  [MGI Ref ID J:89112]

Artis D; Villarino A; Silverman M; He W; Thornton EM; Mu S; Summer S; Covey TM; Huang E; Yoshida H; Koretzky G; Goldschmidt M; Wu GD; de Sauvage F; Miller HR; Saris CJ; Scott P; Hunter CA. 2004. The IL-27 receptor (WSX-1) is an inhibitor of innate and adaptive elements of type 2 immunity. J Immunol 173(9):5626-34. [PubMed: 15494513]  [MGI Ref ID J:93739]

Awasthi A; Carrier Y; Peron JP; Bettelli E; Kamanaka M; Flavell RA; Kuchroo VK; Oukka M; Weiner HL. 2007. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol 8(12):1380-9. [PubMed: 17994022]  [MGI Ref ID J:127774]

Bancroft AJ; Humphreys NE; Worthington JJ; Yoshida H; Grencis RK. 2004. WSX-1: a key role in induction of chronic intestinal nematode infection. J Immunol 172(12):7635-41. [PubMed: 15187144]  [MGI Ref ID J:90821]

Collison LW; Delgoffe GM; Guy CS; Vignali KM; Chaturvedi V; Fairweather D; Satoskar AR; Garcia KC; Hunter CA; Drake CG; Murray PJ; Vignali DA. 2012. The composition and signaling of the IL-35 receptor are unconventional. Nat Immunol 13(3):290-9. [PubMed: 22306691]  [MGI Ref ID J:181328]

Do JS; Visperas A; Oh K; Stohlman SA; Min B. 2012. Memory CD4 T cells induce selective expression of IL-27 in CD8+ dendritic cells and regulate homeostatic naive T cell proliferation. J Immunol 188(1):230-7. [PubMed: 22116827]  [MGI Ref ID J:180589]

Fitzgerald DC; Zhang GX; El-Behi M; Fonseca-Kelly Z; Li H; Yu S; Saris CJ; Gran B; Ciric B; Rostami A. 2007. Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat Immunol 8(12):1372-9. [PubMed: 17994023]  [MGI Ref ID J:127773]

Fujimoto H; Hirase T; Miyazaki Y; Hara H; Ide-Iwata N; Nishimoto-Hazuku A; Saris CJ; Yoshida H; Node K. 2011. IL-27 Inhibits Hyperglycemia and Pancreatic Islet Inflammation Induced by Streptozotocin in Mice. Am J Pathol 179(5):2327-36. [PubMed: 21925473]  [MGI Ref ID J:177366]

Furukawa M; Takaishi H; Takito J; Yoda M; Sakai S; Hikata T; Hakozaki A; Uchikawa S; Matsumoto M; Chiba K; Kimura T; Okada Y; Matsuo K; Yoshida H; Toyama Y. 2009. IL-27 abrogates receptor activator of NF-kappaB ligand-mediated osteoclastogenesis of human granulocyte-macrophage colony-forming unit cells through STAT1-dependent inhibition of c-Fos. J Immunol 183(4):2397-406. [PubMed: 19620301]  [MGI Ref ID J:151552]

Gwyer Findlay E; Villegas-Mendez A; de Souza JB; Inkson CA; Shaw TN; Saris CJ; Hunter CA; Riley EM; Couper KN. 2013. IL-27 Receptor Signaling Regulates CD4+ T Cell Chemotactic Responses during Infection. J Immunol 190(9):4553-61. [PubMed: 23536628]  [MGI Ref ID J:195517]

Hall AO; Beiting DP; Tato C; John B; Oldenhove G; Lombana CG; Pritchard GH; Silver JS; Bouladoux N; Stumhofer JS; Harris TH; Grainger J; Wojno ED; Wagage S; Roos DS; Scott P; Turka LA; Cherry S; Reiner SL; Cua D; Belkaid Y; Elloso MM; Hunter CA. 2012. The Cytokines Interleukin 27 and Interferon-gamma Promote Distinct Treg Cell Populations Required to Limit Infection-Induced Pathology. Immunity 37(3):511-23. [PubMed: 22981537]  [MGI Ref ID J:187660]

Hashimoto Y; Kurita M; Matsuoka M. 2009. Identification of soluble WSX-1 not as a dominant-negative but as an alternative functional subunit of a receptor for an anti-Alzheimer's disease rescue factor Humanin. Biochem Biophys Res Commun 389(1):95-9. [PubMed: 19703422]  [MGI Ref ID J:153530]

Holscher C; Holscher A; Ruckerl D; Yoshimoto T; Yoshida H; Mak T; Saris C; Ehlers S. 2005. The IL-27 receptor chain WSX-1 differentially regulates antibacterial immunity and survival during experimental tuberculosis. J Immunol 174(6):3534-44. [PubMed: 15749890]  [MGI Ref ID J:97706]

Ilarregui JM; Croci DO; Bianco GA; Toscano MA; Salatino M; Vermeulen ME; Geffner JR; Rabinovich GA. 2009. Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat Immunol 10(9):981-91. [PubMed: 19668220]  [MGI Ref ID J:151758]

Iwasaki Y; Fujio K; Okamura T; Yanai A; Sumitomo S; Shoda H; Tamura T; Yoshida H; Charnay P; Yamamoto K. 2013. Egr-2 transcription factor is required for Blimp-1-mediated IL-10 production in IL-27-stimulated CD4(+) T cells. Eur J Immunol 43(4):1063-73. [PubMed: 23349024]  [MGI Ref ID J:195056]

Jeon SG; Kayama H; Ueda Y; Takahashi T; Asahara T; Tsuji H; Tsuji NM; Kiyono H; Ma JS; Kusu T; Okumura R; Hara H; Yoshida H; Yamamoto M; Nomoto K; Takeda K. 2012. Probiotic Bifidobacterium breve induces IL-10-producing Tr1 cells in the colon. PLoS Pathog 8(5):e1002714. [PubMed: 22693446]  [MGI Ref ID J:195381]

Kim G; Shinnakasu R; Saris CJ; Cheroutre H; Kronenberg M. 2013. A Novel Role for IL-27 in Mediating the Survival of Activated Mouse CD4 T Lymphocytes. J Immunol 190(4):1510-8. [PubMed: 23335749]  [MGI Ref ID J:193497]

McAleer JP; Saris CJ; Vella AT. 2011. The WSX-1 pathway restrains intestinal T-cell immunity. Int Immunol 23(2):129-37. [PubMed: 21233255]  [MGI Ref ID J:168576]

Miyazaki Y; Inoue H; Matsumura M; Matsumoto K; Nakano T; Tsuda M; Hamano S; Yoshimura A; Yoshida H. 2005. Exacerbation of experimental allergic asthma by augmented Th2 responses in WSX-1-deficient mice. J Immunol 175(4):2401-7. [PubMed: 16081811]  [MGI Ref ID J:107500]

Miyazaki Y; Shimanoe Y; Wang S; Yoshida H. 2008. Amelioration of delayed-type hypersensitivity responses by IL-27 administration. Biochem Biophys Res Commun 373(3):397-402. [PubMed: 18572017]  [MGI Ref ID J:139190]

Murugaiyan G; Beynon V; Pires Da Cunha A; Joller N; Weiner HL. 2012. IFN-gamma limits Th9-mediated autoimmune inflammation through dendritic cell modulation of IL-27. J Immunol 189(11):5277-83. [PubMed: 23125412]  [MGI Ref ID J:190977]

Murugaiyan G; Mittal A; Weiner HL. 2010. Identification of an IL-27/osteopontin axis in dendritic cells and its modulation by IFN-gamma limits IL-17-mediated autoimmune inflammation. Proc Natl Acad Sci U S A 107(25):11495-500. [PubMed: 20534530]  [MGI Ref ID J:161596]

Pot C; Jin H; Awasthi A; Liu SM; Lai CY; Madan R; Sharpe AH; Karp CL; Miaw SC; Ho IC; Kuchroo VK. 2009. Cutting edge: IL-27 induces the transcription factor c-Maf, cytokine IL-21, and the costimulatory receptor ICOS that coordinately act together to promote differentiation of IL-10-producing Tr1 cells. J Immunol 183(2):797-801. [PubMed: 19570826]  [MGI Ref ID J:151633]

Shainheit MG; Saraceno R; Bazzone LE; Rutitzky LI; Stadecker MJ. 2007. Disruption of interleukin-27 signaling results in impaired gamma interferon production but does not significantly affect immunopathology in murine schistosome infection. Infect Immun 75(6):3169-77. [PubMed: 17403877]  [MGI Ref ID J:121923]

Shimizu S; Sugiyama N; Masutani K; Sadanaga A; Miyazaki Y; Inoue Y; Akahoshi M; Katafuchi R; Hirakata H; Harada M; Hamano S; Nakashima H; Yoshida H. 2005. Membranous glomerulonephritis development with Th2-type immune deviations in MRL/lpr mice deficient for IL-27 receptor (WSX-1). J Immunol 175(11):7185-92. [PubMed: 16301622]  [MGI Ref ID J:122148]

Sonoda KH; Yoshimura T; Takeda A; Ishibashi T; Hamano S; Yoshida H. 2007. WSX-1 plays a significant role for the initiation of experimental autoimmune uveitis. Int Immunol 19(1):93-8. [PubMed: 17118967]  [MGI Ref ID J:116610]

Stumhofer JS; Laurence A; Wilson EH; Huang E; Tato CM; Johnson LM; Villarino AV; Huang Q; Yoshimura A; Sehy D; Saris CJ; O'Shea JJ; Hennighausen L; Ernst M; Hunter CA. 2006. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol 7(9):937-45. [PubMed: 16906166]  [MGI Ref ID J:112649]

Stumhofer JS; Tait ED; Quinn WJ 3rd; Hosken N; Spudy B; Goenka R; Fielding CA; O'Hara AC; Chen Y; Jones ML; Saris CJ; Rose-John S; Cua DJ; Jones SA; Elloso MM; Grotzinger J; Cancro MP; Levin SD; Hunter CA. 2010. A role for IL-27p28 as an antagonist of gp130-mediated signaling. Nat Immunol 11(12):1119-26. [PubMed: 21057510]  [MGI Ref ID J:167324]

Summers SA; Phoon RK; Ooi JD; Holdsworth SR; Kitching AR. 2011. The IL-27 receptor has biphasic effects in crescentic glomerulonephritis mediated through Th1 responses. Am J Pathol 178(2):580-90. [PubMed: 21281790]  [MGI Ref ID J:169084]

Troy AE; Zaph C; Du Y; Taylor BC; Guild KJ; Hunter CA; Saris CJ; Artis D. 2009. IL-27 regulates homeostasis of the intestinal CD4+ effector T cell pool and limits intestinal inflammation in a murine model of colitis. J Immunol 183(3):2037-44. [PubMed: 19596985]  [MGI Ref ID J:151585]

Villarino AV; Artis D; Bezbradica JS; Miller O; Saris CJ; Joyce S; Hunter CA. 2008. IL-27R deficiency delays the onset of colitis and protects from helminth-induced pathology in a model of chronic IBD. Int Immunol 20(6):739-52. [PubMed: 18375937]  [MGI Ref ID J:136179]

Villarino AV; Larkin J rd; Saris CJ; Caton AJ; Lucas S; Wong T; de Sauvage FJ; Hunter CA. 2005. Positive and negative regulation of the IL-27 receptor during lymphoid cell activation. J Immunol 174(12):7684-91. [PubMed: 15944269]  [MGI Ref ID J:100864]

Villarino AV; Stumhofer JS; Saris CJ; Kastelein RA; de Sauvage FJ; Hunter CA. 2006. IL-27 limits IL-2 production during Th1 differentiation. J Immunol 176(1):237-47. [PubMed: 16365415]  [MGI Ref ID J:126267]

Wang S; Miyazaki Y; Shinozaki Y; Yoshida H. 2007. Augmentation of antigen-presenting and Th1-promoting functions of dendritic cells by WSX-1(IL-27R) deficiency. J Immunol 179(10):6421-8. [PubMed: 17982030]  [MGI Ref ID J:153872]

Yamanaka A; Hamano S; Miyazaki Y; Ishii K; Takeda A; Mak TW; Himeno K; Yoshimura A; Yoshida H. 2004. Hyperproduction of proinflammatory cytokines by WSX-1-deficient NKT cells in concanavalin A-induced hepatitis. J Immunol 172(6):3590-6. [PubMed: 15004160]  [MGI Ref ID J:88618]

Yoshimura T; Takeda A; Hamano S; Miyazaki Y; Kinjyo I; Ishibashi T; Yoshimura A; Yoshida H. 2006. Two-sided roles of IL-27: induction of Th1 differentiation on naive CD4+ T cells versus suppression of proinflammatory cytokine production including IL-23-induced IL-17 on activated CD4+ T cells partially through STAT3-dependent mechanism. J Immunol 177(8):5377-85. [PubMed: 17015723]  [MGI Ref ID J:139438]

Health & husbandry

Health & Colony Maintenance Information

Animal Health Reports

Room Number           AX18

Colony Maintenance

Breeding & Husbandry	When maintaining a live colony, homozygous mice may be bred together.
Mating System	Heterozygote x Heterozygote         (Female x Male)   10-JUL-12
Diet Information	LabDiet® 5K20

Pricing and Purchasing

Pricing, Supply Level & Notes, Controls

Control Information

	Control
	Wild-type from the colony
	005304 C57BL/6NJ	(approximate)
Considerations for Choosing Controls
Control Pricing Information for Genetically Engineered Mutant Strains.

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.

See Terms of Use tab for General Terms and Conditions

The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX^® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX^® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX^® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.

---

Ordering Information
JAX^® Mice
Surgical and Preconditioning Services
JAX^® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form

Terms of Use

Terms of Use

General Terms and Conditions

For Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license prior to shipping.

Contact information

General inquiries regarding Terms of Use

Contracts Administration

phone:	207-288-6470
fax:	207-288-6655

JAX^® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.